西罗莫司通过肿瘤选择性增强病毒复制提高溶瘤病毒 M1 的疗效
Sirolimus potentiates oncolytic Virus M1 efficacy through tumor-selective augmentation of viral replication.
西罗莫司通过 mTOR 抑制和 I 型干扰素信号抑制,选择性增强肿瘤内的病毒复制,从而增强 M1 溶瘤病毒疗法,且不依赖于 CD8 T 细胞介导的免疫。
ALL SOURCES
Sirolimus potentiates oncolytic Virus M1 efficacy through tumor-selective augmentation of viral replication.
西罗莫司通过 mTOR 抑制和 I 型干扰素信号抑制,选择性增强肿瘤内的病毒复制,从而增强 M1 溶瘤病毒疗法,且不依赖于 CD8 T 细胞介导的免疫。
From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.
免疫治疗,尤其是CAR-T 细胞疗法,已经彻底改变了血液系统恶性肿瘤和自身免疫性疾病的治疗。
Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltrati
依据:免疫病毒治疗已成为一种有前景的癌症治疗手段,因为它可通过全身免疫刺激直接以细胞毒方式清除肿瘤。
Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma.
溶瘤病毒(OVs)通过直接溶瘤活性和免疫调节转基因的表达介导抗癌效应。
Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy.
在创新性癌症治疗策略领域,溶瘤痘苗病毒(VV)作为有前景的载体已日益受到关注。
Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway.
RFH通过激活cGAS-STING通路显著增强了LTX-315对原位HCC的疗效。
NK cell-based immunotherapy in hepatocellular carcinoma: An attractive therapeutic option for the next decade.
肝细胞癌(HCC)是肝癌的主要亚型,由于诊断晚、进展快,治疗面临重大挑战。
共 7 条
MEMBER ACCOUNT
登录成功会直接打开下一页。